机器人辅助与开放胰十二指肠切除术治疗胰头癌(DIPLOMA-2x2):国际多中心患者与评估者盲法随机对照非劣效性试验研究方案
DIPLOMA-2x2是一项国际多中心、患者与评估者盲法、随机对照非劣效性试验,旨在比较机器人辅助胰十二指肠切除术(RPD)与开放胰十二指肠切除术(OPD)治疗可切除胰头癌的肿瘤学安全性(以R0切除率判定),并假设RPD在肿瘤学根治性上非劣于OPD、在功能恢复时间上优于OPD。计划纳入413例患者(含DIPLOMA-2已随机137例及新招募276例),按2:1随机分配至RPD或OPD组,主要终点为病理R0切除率(非劣效界值-7%)。
要点
- RPD对比OPD的肿瘤学安全性尚缺乏随机证据,本试验以病理R0切除率作为主要终点。
- RPD非劣效界值为-7%,关键次要终点功能恢复时间采用优效性检验。
- 纳入标准为≥18岁、疑似或证实可切除的PDAC或DCC且无血管侵犯的患者。
核心结论
- DIPLOMA-2x2旨在验证在高容量中心由经验丰富术者施行的RPD,其肿瘤学安全性(R0切除率)非劣于OPD,并在功能恢复时间上优于OPD。
研究设计与样本
- 研究者发起的国际多中心、患者与评估者盲法、随机对照非劣效性试验,覆盖7个国家20家高容量三级转诊医院。
- 纳入413例患者(DIPLOMA-2已随机137例,DIPLOMA-2x2新招募276例),按2:1随机分配至RPD或OPD组。
- 随机分层因素为肿瘤指征(证实PDAC vs 其他)和术前胰瘘风险(高 vs 低)。
- 术者最低经验为60例RPD和60例OPD,中心启动前年RPD量至少30例。
主要发现
- 主要终点为病理R0切除率(pR0;手术切缘和解剖表面>1 mm肿瘤 clearance,前表面0 mm clearance),非劣效界值为-7%。
- 关键次要终点为功能恢复时间,采用优效性检验。
- 其他次要终点包括淋巴结检出数、辅助治疗启动/完成、辅助治疗开始时间、无病生存和总生存、生活质量及成本效果。
- 安全性终点包括重大并发症(Clavien-Dindo分级≥III)、严重不良事件和90天死亡率。
关键数值与推荐
- 主要分析基于改良意向性治疗原则,纳入所有接受切除的患者。
- 短期结局随访至术后90天,生存随访至60个月。
- 病理评估采用盲法,随机抽取10%标本进行中心复核。
临床怎么用
- 若结果证实RPD非劣效于OPD,可为可切除胰头癌选择机器人辅助手术提供高级别随机证据。
- 试验强调术者经验与中心手术量门槛,结果外推需考虑高容量中心的实施条件。
局限性
- 试验方案尚未报告实际结果,无法评估干预效应的实际大小。
- 患者盲法仅维持至术后第5天,远期结局评估可能受限于开放标签。
- 结果外推性受限于高容量中心及经验丰富术者的参与条件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robot-assisted pancreatoduodenectomy (RPD) is increasingly performed for cancer in the pancreatic head. Randomised evidence confirming its oncological safety and efficacy is lacking. The DIPLOMA-2x2 trial aims to compare the oncological safety of RPD versus OPD in terms of radicality (microscopically radical resection [R0] resection). We hypothesise that RPD is non-inferior to OPD in terms of radicality and superior regarding time to functional recovery. METHODS: The DIPLOMA-2x2 trial is an investigator-initiated, international, multicentre, patient- and assessor-blinded randomised non-inferiority trial. The trial was conducted as a roll-over of the DIPLOMA-2 trial and includes 20 high-volume tertiary referral hospitals in 7 countries. Minimum surgeon's experience is 60 RPD and 60 OPD, with a minimum annual centre volume of 30 RPD prior to trial initiation. Eligible patients are adults (≥18 years) with suspected or proven upfront resectable pancreatic ductal adenocarcinoma (PDAC) and distal cholangiocarcinoma (DCC) without any vascular involvement. Participants are randomised in a 2:1 ratio to RPD or OPD, respectively, stratified by tumour indication (proven PDAC versus other) and preoperative pancreatic fistula risk (high versus low). In total, 413 patients will be included, of which 137 previously randomised in DIPLOMA-2 and 276 newly recruited in DIPLOMA-2x2. Patients are blinded up to postoperative day 5. Primary outcome is pathological R0-resection rate (pR0; >1 mm tumour clearance at surgical resection margins and anatomical surfaces, 0 mm clearance at anterior surface), tested for non-inferiority with a -7% margin. Pathological assessment is blinded, and a randomly selected 10% of specimen will undergo central review. The key secondary outcome, tested for superiority, is time to functional recovery. Other secondary outcomes include lymph node retrieval, initiation/completion of adjuvant therapy, time to start of adjuvant therapy, disease-free and overall survival, quality of life, and cost-effectiveness. Safety outcomes include major complications (Clavien-Dindo grade ≥ III), serious adverse events, and 90-day mortality. Primary analyses will be based on the modified intention-to-treat principle, including all patients who underwent resection. Postoperative follow-up is up to 90 days for short-term outcomes and up to 60 months for survival. DISCUSSION: The DIPLOMA-2x2 trial evaluates whether RPD is oncologically safe compared to OPD in patients with upfront resectable PDAC and DCC in experienced high-volume centres. TRIAL REGISTRATION: ISRCTN27483786. Registered: January 11, 2021 (updated: February 6, 2025). First enrolment: January 3, 2021. Expected completion of enrolment: May 2026.
引用
- de Graaf N, Bruna CL, Menso JE, et al. Robot-assisted versus open pancreatoduodenectomy for cancer in the pancreatic head (DIPLOMA-2x2): study protocol for an international multicentre patient- and assessor-blinded randomized controlled non-inferiority trial. Trials. 2026. PMID: 42464359. doi:10.1186/s13063-026-09692-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。